Recurrent compulsive thoughts and behaviors caused by obsessive-compulsive disorder (OCD) against the subjective wishes of the individual can lead to significant distress and anxiety for the patient. To improve the therapeutic effect on patients with severe OCD, to study the positive impact of environmental art design of cultural architecture under the characteristics of modern aesthetic psychology on patients with OCD.

Twenty-five patients with obsessive-compulsive disorder were selected as the experimental group and another 25 patients with obsessive-compulsive disorder as the control group. Maudsley Obsessive-Compulsive Inventory (MOCI) was used to collect data on the two groups. Learning and appreciating seven days of aesthetic art design as a cycle and three cycles as a course of treatment. In each process, the two groups of patients were tested for obsessive-compulsive disorder scores until the end of 5 courses.

The mean scores of the experimental and control groups were 33 and 35 after one course of treatment and 22 and 36 after five treatment methods, respectively. The experimental group significantly improved symptom relief, emotion regulation, and psychological comfort, while the control group had no significant change.

Creating a building environment with aesthetic value and emotional resonance can significantly alleviate the symptoms of OCD and improve the audience’s emotional regulation ability and psychological comfort. Therefore, attention should be paid to the application and publicity of aesthetic and psychological characteristics in cultural architecture design to provide comfortable environmental art experiences for obsessive-compulsive disorder audiences.

DiGeorge Syndrome is a microdeletion of chromosome 22q11.2 and is most commonly de novo. Manifestations of DiGeorge are wide-spread including cardiac malformations, palatal abnormalities, intellectual disability, hypocalcemia, dysmorphic facial features, and psychiatric disorders (psychotic disorders, Autism, ADHD, etc). This case report highlights difficulties with diagnosis and treatment of psychosis in DiGeorge. This 29 yo male with history of DiGeorge and associated cardiac anomalies presented to the outpatient clinic with prior diagnoses of schizoaffective disorder, bipolar disorder, DMDD, autism, and ADHD. Patient denied all symptoms, though mother noted hallucinations for 5–6 years. He was previously on aripiprazole and divalproex and developed a resting tremor. With family history of Parkinson’s disease (PD), increased risk of PD in DiGeorge, and no improvement in tremor with dose reduction of aripiprazole or discontinuation of divalproex, neurology diagnosed PD, which was later negated when tremor resolved with complete discontinuation of aripiprazole. In our clinic we slowly increased divalproex and olanzapine, though parent concern of sedation limited higher doses. Patient had moderate improvement in symptoms per parents, but after several months on moderate-dose olanzapine, he developed a tremor. Sensitivity to extrapyramidal symptoms limits medication selection. Furthermore, QT prolongation in a population with cardiac abnormalities poses a unique risk. Given complexity and poor response, we researched pathogenesis and treatment of psychosis in DiGeorge.

We reviewed literature on PubMed with keywords including “DiGeorge,” “treatment,” “psychosis.” Specifically, we looked at articles addressing treatment response, efficacy, side effects, novel treatments, and the pathogenesis as it relates to treatment.

Literature indicates that psychotic symptoms are more treatment resistant compared to psychotic disorders not associated with DiGeorge and there is little consensus on which antipsychotics are more effective. The 22q11.2 deletion contains the gene segment for catechol-O-methyltransferase (COMT) and the resulting COMT deficiency leads to excess catecholamines. The presence of the low activity COMT variant on the remaining allele is associated with possibly more severe psychiatric symptoms. Metyrosine may be a potential medication in the treatment of psychosis in DiGeorge by interfering with dopamine synthesis. Overall there is sparse research on treatment of psychosis in DiGeorge and a lack of firm recommendations.

This case study exemplifies the need for further research on DiGeorge Syndrome and treatment of psychosis. Treatment is complicated by cardiac abnormalities, comorbid neuropsychiatric conditions confounding diagnosis, and little research on treatments that target the unique pathogenesis. Research is inconsistent concerning recommendations and novel treatments are primarily anecdotal.

No Funding

The incarceration of women is a risk factor for phobias in women. Depth phobia can seriously affect patients’ quality of life and even induce the risk of suicide. However, this phenomenon is common in many countries and regions. To study the social and psychological reasons for this phenomenon and propose strategies to help patients escape their fear.

Fifty women with a history of incarceration and phobias were selected as the experimental group, and 50 women with a history of imprisonment and no phobias were selected as the control group. The Anxiety Disorders Interview Schedule for DSM-IV (ADDIS-IV) was used to analyze the 100 women comprehensively.

The experimental group had a mean score of 88, and the control group had a mean score of 72 out of 100 on the 20-item comprehensive assessment. The study found that factors such as domestic violence, gender discrimination, mental health, and local culture may lead to the incarceration of women, and women with excessive life stress and a history of incarceration are more likely to develop phobias. In addition, the local social structure and legal system may also lead to the imprisonment and phobias of women.

The results showed domestic violence and gender discrimination were the leading causes of women’s incarceration and phobias. Therefore, the provision of psychosocial counseling and treatment services should be strengthened to reduce the incidence of incarceration and phobia among women.

Aripiprazole 2-month ready-to-use 960 mg (Ari 2MRTU 960) is a new long-acting injectable (LAI) antipsychotic formulation for gluteal administration every 2 months. This 32-week trial evaluated the safety, pharmacokinetics, and efficacy of multiple-dose administration of Ari 2MRTU 960 in clinically stable adults with schizophrenia or bipolar I disorder (BP-I), versus that of aripiprazole once-monthly 400 mg (AOM 400; an LAI indicated for the maintenance treatment of schizophrenia in adult patients stabilized with oral aripiprazole [indication varies by country]). Safety and efficacy outcomes in the subpopulation of patients with schizophrenia are reported here.

Patients with schizophrenia were randomized to receive Ari 2MRTU 960 every 56±2 days or AOM 400 every 28±2 days. Safety and tolerability assessments included adverse event (AE) reporting, Visual Analogue Scale [VAS] scores (scale range: 0–100) for patient-reported injection site pain, and extrapyramidal symptom (EPS) monitoring. Efficacy was evaluated at Week 32 using mean (standard deviation [SD]) Clinical Global Impression – Improvement (CGI-I) score, and mean (SD) change from baseline in Clinical Global Impression – Severity (CGI-S) score, Subjective Well-being under Neuroleptic Treatment – Short Form [SWN-S] Total score, and Positive and Negative Syndrome Scale (PANSS) Total score.

Study completion rate was 79.3% (73/92 patients) in the Ari 2MRTU 960 group and 67.7% (63/93 patients) in the AOM 400 group. Demographics and disease characteristics were well balanced between groups at baseline (mean [SD] PANSS Total score: Ari 2MRTU 960, 62.0 [13.5]; AOM 400, 61.8 [13.5]; mean (SD) CGI-S score: Ari 2MRTU 960, 3.3 [0.9]; AOM 400, 3.1 [0.9]). Treatment-emergent AE (TEAE) incidence was 66.3% with Ari 2MRTU 960 and 63.4% with AOM 400. The most frequent TEAEs were increased weight (Ari 2MRTU 960, 21.7%; AOM 400, 18.3%) and injection site pain (Ari 2MRTU 960, 15.2%; AOM 400, 9.7%). Mean (SD) VAS score for pain after last injection was 1.5 (4.58) with Ari 2MRTU 960 and 1.3 (2.79) with AOM 400. Minimal change was seen in EPS in either group. At Week 32, mean (SD) CGI-I score was similar between groups (Ari 2MRTU 960, 3.5 [1.0]; AOM 400, 3.6 [0.9]). Minimal change from baseline was seen at Week 32 in CGI-S score and SWN-S Total score. There was no clinically meaningful difference between the groups for PANSS Total score (difference of least squares mean change from baseline [95% confidence interval]: -0.9 [-3.5, 1.8]; p=0.5154).

In patients with schizophrenia, administration of Ari 2MRTU 960, as compared with AOM 400, was generally well tolerated, and clinical stability was maintained during the study.

Otsuka Pharmaceutical Development & Commercialization, Inc. (Princeton, NJ, USA) and H. Lundbeck A/S (Valby, Denmark).

Social Anxiety Disorder (SAD) is a highly prevalent anxiety disorder characterized by the excessive or irrational fear of particular external objects and situations. The study proposes to treat social anxiety disorders in children with the help of head acupuncture therapy. Considering the pathological features of anxiety disorders in children, a combined intervention with traditional music aesthetic education is also proposed.

Children suffering from social anxiety disorder were taken as research subjects and randomly divided into experimental and control groups. Both groups were treated with head acupuncture. The experimental group added a traditional music aesthetic education intervention to help the children relieve their anxiety through music and learning. The experimental intervention time was six weeks, and the experimental data were statistically analyzed with the help of the Hamilton Anxiety Scale (HAMA) and Social Anxiety Scale for Children (SASC). The difference was statistically significant at P<0.05.

After the experimental intervention, it was found that there was a statistically significant difference between the social anxiety scale scores of the two groups of children (P<0.05), with a significant effect of decreasing the scores of the SASC scale for children in the experimental group by more than 15%.

Aesthetic education is a combination of aesthetic and beauty teaching, and its combination with cephalic acupuncture therapy can better alleviate the symptoms of children’s social anxiety disorder and help and guide their cognitive behavior.

Lumateperone is an FDA-approved antipsychotic to treat schizophrenia and depressive episodes associated with bipolar I or bipolar II disorder as monotherapy and as adjunctive therapy with lithium or valproate. This post hoc analysis investigated the efficacy and tolerability of lumateperone in patients with schizophrenia via number needed to treat (NNT), number needed to harm (NNH), and likelihood to be helped or harmed (LHH).

Data were pooled from three late-phase 4–6 week placebo-controlled studies of lumateperone 42 mg/day in adults with schizophrenia and an acute exacerbation of psychosis (Study 005 [NCT01499563], Study 301 [NCT02282761], Study 302 [NCT02469155]). NNT and NNH were calculated vs placebo for several different Positive and Negative Syndrome Scale [PANSS] Total score response cutoffs (percent reduction from baseline) and for adverse events (AEs), respectively.

In the two informative studies (placebo, n=221; lumateperone, n=224), the NNT vs placebo for lumateperone was statistically significant for PANSS Total score reductions from baseline to 4 weeks/endpoint of ≥20% (NNT=9, 95% confidence interval [CI] 5–36) and ≥30% (NNT=8; 95%CI 5–21). In all studies pooled (placebo, n=412; lumateperone, n=406), study discontinuations due to AEs were uncommon and the NNH (389) was not statistically significant from placebo. The only AE with NNH vs placebo <10 was somnolence/sedation (NNH=8; 95%CI 6–12). With lumateperone treatment, weight gain ≥7% from baseline was similar to placebo (NNH=112) and fewer patients experienced akathisia than placebo. Lumateperone LHH ratios were >>1 for all AEs (range 13.6–48.6) except somnolence/sedation (LHH~1).

Lumateperone’s benefit-risk profile was favorable in late-phase schizophrenia trials.

Intra-Cellular Therapies, Inc.

HP-3070, a once-daily asenapine transdermal system, is FDA-approved for adults with schizophrenia. In a pivotal phase 3 randomized controlled study, patients with schizophrenia who were treated once daily with HP-3070 demonstrated significant improvement in Positive and Negative Syndrome Scale (PANSS) total scores compared with placebo. The PANSS score’s five-factor structure can also assess treatment efficacy across different domains. This post-hoc analysis of the pivotal study evaluated the efficacy of HP-3070 by examining these domains.

In the pivotal phase 3 study, adults with acute exacerbations of schizophrenia were randomized to 6 weeks of treatment with HP-3070 3.8mg/24h, 7.6mg/24h, or placebo. Factor analysis of PANSS scores was performed using five domains (negative symptoms, positive symptoms, disorganized thought, uncontrolled hostility/excitement, anxiety/depression). Mixed-model repeated-measures (MMRM) analysis included change from baseline in PANSS factor score as the repeated dependent variable, with country, treatment, visit, treatment by visit interaction, and baseline PANSS score as covariates.

The analysis included 607 patients. Least-squares mean estimates (standard error) of the difference from placebo in change from baseline to Week 6 for each factor were as follows: negative symptoms, 3.8mg/24h, -0.9 (0.43), P=0.045, and 7.6mg/24h, -0.4 (0.43), P=0.41; positive symptoms, 3.8mg/24h, -2.3 (0.57), P<0.001, and 7.6mg/24h, -2.0 (0.57), P<0.001; disorganized thought, 3.8mg/24h, -1.5 (0.38), P<0.001, and 7.6mg/24h, -0.9 (0.38), P=0.03; uncontrolled hostility/excitement: 3.8mg/24h, -1.1 (0.30), P<0.001, and 7.6mg/24h -0.9 (0.30), P=0.002; anxiety/depression, 3.8mg/24h, -0.5 (0.31), P=0.14, and 7.6mg/24h, -0.6 (0.31), P=0.07.

HP-3070 demonstrated treatment effects on a PANSS five-factor model, with the results indicating impact on negative symptoms, positive symptoms, disorganized thought, uncontrolled hostility/excitement, and anxiety/depression. These findings suggest that HP-3070 may address a broad range of symptoms in schizophrenia.

Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical, Co.

Depression, a psychological disorder, often manifests in persistent melancholy and inattention. Psychologist Sigmund Freud believes that literature and art can better channel individual emotional stress, so the study is based on the course of civics teaching joint innovation of aesthetic education teaching to achieve a positive and effective intervention in the mental health of college students.

This research took depressed college students from one university as the research subjects. They were divided into a control group (conventional civics teaching method) and an experimental group (course civics combined with art appreciation method), and the students were guided to improve the dissolution of depression and depressive symptoms. The intervention time was six weeks and was assessed with the help of the Self-Depression Scale for Depression (SDS) and the Quality of Life Measurement Scale (WHOQOL-BREF).

After the experimental intervention, the SDS scores of the experimental group and the WHOQOL-BREF sub-scales were higher than those of the control group, and the difference was statistically significant (P<0.05). The mean score of the SDS scale in the experimental group had a score difference of more than 15 points before and after the experiment.

The joint study of Civics and Aesthetic Education gives students a new cognition of their own emotions and thoughts, and the change of “cognitive bias” makes the depression symptoms of college students to a greater extent.

Social anxiety disorder is characterized by avoidance of interpersonal relationships and a generalized impairment of emotion recognition and regulation. Protecting the individual’s consumer rights can be difficult when this emotion is expressed in consumer relationships. Compared with other therapies, Emotionally Focused Therapy focuses more on the individual’s emotional processing. Therefore, the study proposes to use emotion-focused therapy and psychological distance theory to intervene in patients with social anxiety disorder and help them better control their emotional management.

Consumers with social anxiety disorder were selected as research subjects and randomly divided into an experimental group (conventional psychological intervention) and a control group (emotion-focused therapy combined with psychological distance-related theory), respectively, to provide reasonable guidance for individual emotions. Before and after the experiment, the results were analyzed with the help of the Social Anxiety Subscale of the Self-Consciousness Scale and SPSS23.0.

After the experimental intervention, it was found that there was a statistically significant difference between the social anxiety scale scores of the two groups of patients (P<0.05), and the total scale scores of the experimental group and the control group were (12.34 ± 4.28) and (18.17 ± 2.13), respectively.

Emotional aggregation therapy can better enable social anxiety disorder patients to focus more on their own emotions, and psychological distance theory research can invariably draw closer to the degree of closeness between the intervener and the interviewees so that the efficacy of the treatment has a high degree of applicability and effectiveness.

Aripiprazole 2-month ready-to-use 960 mg (Ari 2MRTU 960) is a new long-acting injectable (LAI) antipsychotic formulation for gluteal administration every 2 months. This 32-week trial evaluated the safety, pharmacokinetics, and efficacy of multiple-dose administration of Ari 2MRTU 960 in clinically stable adults with schizophrenia or BP-I, versus that of aripiprazole once-monthly 400 mg (AOM 400; an LAI indicated for the maintenance treatment of schizophrenia in adult patients stabilized with oral aripiprazole and maintenance monotherapy treatment of BP-I [indication varies by country]). Safety and efficacy outcomes in the subpopulation of patients with BP-I are reported here.

Patients with BP-I were randomized to receive Ari 2MRTU 960 every 56±2 days or AOM 400 every 28±2 days. Safety and tolerability assessments included adverse event (AE) reporting, Visual Analogue Scale (VAS) scores (scale range: 0–100) for patient-reported injection site pain, and extrapyramidal symptom (EPS) monitoring. Efficacy was assessed at Week 32 by Clinical Global Impression – Improvement (CGI-I), Clinical Global Impression – Bipolar Version (CGI-BP), Subjective Well-being under Neuroleptic Treatment – Short Form (SWN-S), Montgomery–Åsberg Depression Rating Scale (MADRS), and Young Mania Rating Scale (YMRS).

Study completion rate was 72.5% (29/40 patients) in the Ari 2MRTU 960 group and 70.7% (29/41 patients) in the AOM 400 group. Demographics and baseline disease characteristics were generally well balanced between treatment groups. Treatment-emergent AE (TEAE) incidence was 82.5% with Ari 2MRTU 960 and 87.8% with AOM 400. The most frequent TEAEs were increased weight (Ari 2MRTU 960, 25.0%; AOM 400, 26.8%) and injection site pain (Ari 2MRTU 960, 25.0%; AOM 400, 7.3%). Mean (standard deviation [SD]) VAS score for pain after last injection was 1.2 (2.07) with Ari 2MRTU 960 and 1.3 (2.19) with AOM 400. Minimal change was seen in EPS in either group. At Week 32, mean (SD) CGI-I score was 3.1 [1.2] with Ari 2MRTU 960 and 3.2 [1.5] with AOM 400, and there was minimal mean (SD) change from baseline in CGI-BP score (Ari 2MRTU 960, -0.2 [1.0]; AOM 400, -0.6 [1.2]). Mean (SD) change from baseline in SWN-S Total score was 10.3 (16.1) with Ari 2MRTU 960 and 3.4 (21.4) with AOM 400. There was no clinically meaningful difference between the groups in MADRS Total score or YMRS Total score (difference of least squares mean change from baseline [95% confidence interval]: MADRS Total score -2.1 [-6.3, 2.1], p=0.3185; YMRS Total score 0.1 [-1.8, 2.1], p=0.8995).

In patients with BP-I, Ari 2MRTU 960 was generally well tolerated, and clinical stability was maintained during the study.

Otsuka Pharmaceutical Development & Commercialization, Inc. (Princeton, NJ, USA) and H. Lundbeck A/S (Valby, Denmark).

Patients with major depressive disorder (MDD) often have inadequate response to antidepressant treatment (ADT) requiring augmentation with other treatments. Cariprazine is a D3-preferring D3/D2 and serotonin 5-HT1A receptor partial agonist approved to treat schizophrenia and manic, mixed, and depressive episodes of bipolar I disorder. The efficacy of cariprazine as an adjunctive treatment for patients with MDD and inadequate response to ADT alone has been evaluated in phase 2/3 randomized, double-blind, placebo-controlled trials. Post hoc analyses of one phase 3 trial (NCT03738215) evaluated cariprazine + ADT for improving depressive symptoms in subgroups of patients categorized by 1) the level of response to ongoing ADT at baseline and 2) the number of ADTs associated with inadequate response during the current episode.

Patients were randomized to placebo + ADT (n=254), cariprazine 1.5 mg/d + ADT (n=252), or cariprazine 3 mg/d + ADT (n=253) for 6 weeks of double-blind treatment. Post hoc analyses evaluated change from baseline to week 6 in MADRS total score in subgroups of patients who had ≥25%–<50% or <25% response to ongoing ADT at baseline, and in subgroups of patients who had inadequate response to 1 or ≥2 ADTs in the current episode. Analyses used a mixed-effects model for repeated measures; least squares mean differences (LSMD) versus placebo with 95% confidence interval (95% CI) were calculated.

At baseline, 65.1% (n=486) of patients had an ADT response level between 25%–<50% and 34.9% (n=261) of patients had an ADT response level <25%. Mean MADRS total score reductions were greater for cariprazine 1.5 mg/d + ADT versus placebo + ADT in both ADT response subgroups (25%–<50% ADT response: -14.8 vs -11.9, LSMD [95% CI]=-2.3 [-4.2, -0.3]; <25% response to ADT: (-14.7 vs -11.7, LSMD [95% CI]=-2.6 [-5.5, 0.3]). For cariprazine 3 mg/d + ADT, mean change in MADRS total score was numerically greater versus placebo in both response subgroups (25%–<50% response=-14.2, LSMD [95% CI]=-1.5 [-3.5, 0.4]; <25% response= -12.3, LSMD [95% CI]=-0.74 [-3.6, 2.1]). Approximately 86% (n=644) and 14% (n=105) of patients in this study had inadequate response to 1 ADT or ≥2 ADTs, respectively, during the current episode. The LSMD (95% CI) in MADRS total score change for cariprazine 1.5 mg/d + ADT versus placebo + ADT was -2.3 (-4.1, -0.6) in the subgroup of patients with 1 previous ADT and -3.2 [-7.1, 0.8]) in the subgroup of patients with ≥2 previous ADTs. For cariprazine 3 mg/d + ADT, the LSMD (95% CI) in MADRS total score change versus placebo was -0.7 (-2.5, 1.0) in the 1 previous ADT subgroup and -4.7 (-8.8, -0.6) in the ≥2 previous ADTs subgroup.

In these post hoc analyses, cariprazine + ADT was associated with greater reductions in MADRS total score versus placebo regardless of the level of response to ongoing ADT at baseline or number of prior ADT failures in the current episode.

AbbVie

Depression is a kind of depression with the primary clinical manifestation and the duration of the mental and psychological disease, with insomnia, low mood, lack of pleasure, and other symptoms. Presently, the tendency of depression among students from different colleges, universities, and majors is apparent and varies. To better improve the depression situation of college students, the study proposes to guide their mental health from the intervention perspective of education and training mode.

Depressed engineering college students were selected as research subjects and randomly divided into an experimental group (psychological intervention combined with engineering applied talent cultivation model) and a control group (conventional psychological intervention), in which the talent cultivation model was docked with an example of the engineering project. During the experiment, the data were processed and analyzed with the help of the Self Depression Scale (SDS) and SPSS22.0 statistical tools.

After the experimental intervention, it was found that there was a statistically significant difference between the depression scale scores of the two groups of patients (P<0.05), and the improvement of depression in the subjects of the experimental group was significantly better than that of the control group.

The combination of talent cultivation mode and psychological intervention can better help engineering college students to improve their depression, enhance the level and quality of their mental health, and view their studies and work in a more positive frame of mind.

Patients with major depressive disorder (MDD) often do not respond to antidepressant (ADT) monotherapy alone and may require adjunctive treatment to provide adequate symptom relief. Cariprazine (CAR) is a dopamine D3-preferring D3/D2 and serotonin 5-HT1A receptor partial agonist approved to treat adults with schizophrenia and manic, mixed, or depressive episodes of bipolar I disorder. Post hoc analysis of data from a randomized controlled trial evaluated clinically relevant improvements in depressive symptom severity with adjunctive cariprazine in patients with MDD and inadequate response to ADT monotherapy.

Post hoc analysis evaluated data from a randomized, double-blind, placebo-controlled MDD trial (NCT03738215) in patients treated with CAR (1.5 mg/d or 3 mg/d) + ADT or placebo + ADT; the primary outcome was change from baseline to week 6 in Montgomery-Åsberg Depression Rating Scale (MADRS) total score. Post hoc analysis evaluated category shifts from baseline to week 6 in MADRS severity (normal <6, mild 7–19, moderate 20–34, severe ≥35). MADRS severity shifts were reported as the percentage of patients with no change or worsened severity, 1 category improvement, ≥1 category improvement, and ≥2 category improvement. Examples of categorical shifts in depressive symptoms at week 6 include change from severe at baseline to moderate (1 category improvement) and change from severe at baseline to mild (2 category improvement).

Of the 751 patients in the intent-to-treat (ITT) population (CAR: 1.5 mg/d=250, 3.0 mg/d=252; placebo=249), baseline MADRS severity was mild in 1.5%, moderate in 64%, and severe in 35%. Fewer CAR + ADT patients compared to placebo + ADT had no change or worsened MADRS severity at week 6 (CAR: 1.5 mg/d=32%, 3.0 mg/d=33%; placebo=42%). Approximately 68% of patients treated with CAR + ADT demonstrated a MADRS severity improvement of 1 category or greater by week 6 (CAR: 1.5 mg/d=68%, 3.0 mg/d=67%; placebo=58%). A greater percentage of patients in the CAR 1.5 mg/d group also had a 2 or greater category improvement versus CAR 3.0 mg/d or placebo 6 (CAR: 1.5 mg/d=28%, 3.0 mg/d=17%; placebo=19%).

In this post hoc analysis, CAR + ADT was associated with a greater proportion of patients with improvements in depressive symptom severity categories compared with placebo + ADT. These results may suggest that CAR + ADT is associated with clinically meaningful depressive symptom improvement in MDD patients.

AbbVie

ADHD, also known as Attention-deficit hyperactivity disorder (ADHD), has inattention, hyperactivity, conduct disorder, and impulsive behavior as its main clinical manifestations. Visual working memory load is one of the factors that can affect the individual’s attentional performance, so the study proposes to intervene in patients with ADHD with the help of a training form that combines artistic design and the visual aesthetics of colors.

Children with attention deficit hyperactivity disorder (ADHD), meeting the American Diagnostic and Statistical Manual of Mental Disorders, 4th edition criteria, were selected as the study subjects and divided into experimental and control groups using the random table method. Both groups underwent color vision training therapy, strengthening the experimental group regarding graphic design and color aesthetics. The practical test tools included Rey’s Complex Graphic Memory Task and Chinese Children’s Attention Level Scale, and the statistical analysis tool was SPSS23.0, with P<0.05 indicating statistical differences.

In the ceramic art design test experiment, the subjects in the experimental group scored better than the control group in terms of structure and detail (P<0.05), and their concentration level was greatly improved.

The intervention of art design and color visual aesthetics integration has obvious applicability to ADHD patients, with significant efficacy, better control of their attention and behavioral actions, and help to improve the ability of self-management.

With increased social pressure and work intensity, construction workers face increasing mental pressure. In recent years, studies have shown that the incidence rate of mood disorder mania is gradually rising among construction workers in construction engineering. To ensure project progress and worker health, this study analyzed the effectiveness of sodium valproate combined with olanzapine in treating mood disorder mania in construction workers.

One hundred construction workers diagnosed with mood disorder mania were randomly divided into an experimental and a control group, with 50 people in each group. The experimental group was treated with sodium valproate and olanzapine. The control group only used sodium valproate. The experiment lasted three months, and the patient’s status was evaluated using the Beck Ravensen Mania Scale (BRMS). Use Excel and SPSS24.0 to process the data statistically.

After three months of treatment, the manic symptoms in the experimental group improved faster and had fewer side effects. The treatment effectiveness rate of the experimental group was as high as 86%, significantly higher than the control group’s 68%. Proved the effectiveness of sodium valproate combined with olanzapine treatment regimen.

In construction project management, sodium valproate combined with olanzapine can effectively alleviate symptoms and improve workers’ mental health and work efficiency for construction workers suffering from mood disorder mania.

Glycolimia is observed in a plethora of medical conditions including burning mouth syndrome, opioid withdrawal, as well as from a variety of medications including vortioxetine, l-methylfolate, lisdexamfetamine, and gabapentin. While vilazodone, an antidepressant with agonist like effects on 5-HT1A receptors, has been found to induce hyperglycemia, it has not heretofore been reported to induce glycolimia. Such a case is described.

Case study: A 60-year-old, left-handed (pathological) male presented with a past history of depression, minimally responsive to a variety of antidepressant medications, was begun on vilazodone, initially 20 mg and gradually increased to 60 mg a day. On 60 mg a day he noticed severe cravings for sweets, which he had never experienced prior to starting vilazodone. He found he had increased consumption, craving sweet foods including cookies and candy. For instance, in a typical day, he would eat eight Oreos, chocolate-covered graham crackers, one pint of ice cream a day, and he would crave sweets even after feeling satiated after consuming a meal. Along with this increased eating, he gained 20 pounds over the 3 months while on the vilazodone. Upon discontinuing the vilazodone, although the weight didn’t change, the sweet cravings resolved.

Abnormalities on: Neurological examination: Mental status examination: Immediate recall: able to remember 6 digits forwards and 3 digits backwards. Motor examination: Drift testing: right inward drift. Gait examination: unstable tandem gait. Neuropsychiatric examination: Go-No-Go test: 6/6 (normal). Animal Fluency Test: 22 (normal).

There are myriad mechanisms whereby vilazodone may have induced glycolimia. Possibly due to its antidepressant effects, it increased hedonics, generating appetitive behaviors, including enhanced socialization, sexual, and other consumptive behaviors, including eating. Peradventure it may have enhanced motivation and socialization. Along with socialization, there is escalation in social intercourse, with accompanying commensalism. Along with such consumptive behaviors, we could anticipate glycolimia. As a 5-HT1A receptor agonist, possibly vilazodone may have acted on the arcuate pro-opiomelanocortin neurons associated with hyperphagia, with modulation of energy homeostasis in the serotonin pathway. Alternatively, vilazodone may have triggered an enhanced insulin response with secondary reduction in blood sugar, leading to a homeostatic behavioral response of increased glucose intake. In those who are treated with vilazodone, query as to glycolimia is warranted and warning as to potential manifestations of hyperglycemia should be entertained.

No Funding

In recent years, due to academic pressure, changes in interpersonal relationships, and living environments, the mental health problems of college students have gradually become prominent, with obsessive-compulsive disorder (OCD) becoming an indispensable part. Patients with obsessive-compulsive disorder often suffer from recurring obsessive-compulsive beliefs and behaviors, seriously affecting their daily lives and academic performance. Therefore, seeking effective intervention methods is crucial.

The experiment selected 60 students with obsessive-compulsive disorder from a particular school and randomly divided them into an experimental group and a control group, with 30 students in each group. The experimental group received practical teaching of flower arrangement art and acceptance commitment therapy (ACT). The control group only used traditional psychological counseling methods. The experimental period is six months, and the data is statistically processed using SPSS 24.0 and Excel.

After a 6-month intervention, the obsessive-compulsive symptoms in the experimental group were significantly reduced, with a total effective rate of 90%, while the effective rate in the control group was 60%. In addition, the experimental group’s self-efficacy, emotional regulation ability, and quality of life also significantly improved.

The combination of flower arrangement art practice teaching and acceptance commitment therapy has shown sound intervention effects in treating obsessive-compulsive disorder college students. This combined treatment method can not only effectively alleviate obsessive-compulsive symptoms but also enhance the patient’s psychological resilience and self-management ability. Promoting this method has significant practical value in future mental health work.

Hunan Province General Higher Education Teaching Reform Research Project (General Education Project) (No. HNJG-2020-1170).

The Dextroamphetamine Transdermal System (d-ATS) was developed as an alternative to oral amphetamine (AMP) formulations for ADHD. In a pivotal study, d-ATS met primary and secondary efficacy endpoints for ADHD in children and adolescents. Study subjects wore d-ATS for 9 hours, and an improvement in Swanson, Kotkin, Agler, M-Flynn, and Pelham scale (SKAMP) total score was observed from 2 through 12 hours after application. Patients with ADHD may need varying durations of treatment for symptoms from day to day. This analysis describes the exposure-response (E-R) relationship for d-ATS and explores possible outcomes for wear times ≤9 hours under varying assumptions.

A population pharmacokinetic (PK) model was developed to describe AMP disposition following d-ATS administration. This model was used to construct a population pharmacokinetic/pharmacodynamic (PK/PD) model from SKAMP total score data from two pediatric clinical studies to characterize onset and duration of effect after d-ATS administration. The integrated PK/PD model was used to describe the d-ATS E-R relationship and simulate the potential onset and duration of effect of d-ATS in response to various removal times (when <9 hours) by utilizing SKAMP scores as the efficacy measure. Subject-level AMP PK and SKAMP profiles were simulated for d-ATS removal at 4–9 hours post-application under different assumptions for AMP absorption after early patch removal. Modifications were made to the original population PK model to simulate patch removal.

Data from 81 children and 41 adolescents, 6–17 years old, were included. The model provided a reasonable description of the SKAMP score over time, showing an initial decline ~2 hours after patch application. In approximately 50% of children and adolescents, the maximum decline in SKAMP scores was observed within the first 4 hours after patch application. Earlier simulated d-ATS removal times were associated with reduced systemic exposure and earlier return to near-baseline scores across the range of assumptions tested.

Under different assumptions, the graphs changed modestly but not dramatically. For example, with moderate/conservative assumptions, following a 9-hour wear time, SKAMP scores returned to within 90% of baseline value in ~49% of subjects by 12 hours and ~80% of subjects by 16 hours. Following a 4-hour wear time, percentages were ~74% by 12 hours and ~95% by 16 hours.

Simulation results suggest that the duration of d-ATS efficacy may be related to wear time, which can be adjusted according to treatment needs, consistent with published observations for another transdermal stimulant. The d-ATS patch provides the ability to control medication exposure by shortening wear time, allowing treatment duration to be individualized and optimized in ADHD patients who have varying schedules and needs.

Noven Pharmaceuticals, Inc.

Demand for digital mental health tools has risen since the start of the COVID-19 pandemic; however, their evolving use in mental health care is not well understood. We surveyed mental health care professionals (HCPs) before and after the onset of the pandemic and assessed how use of and attitudes about digital technology changed.

We distributed a digital health survey to HCPs in the United States in 2019 (pre-pandemic; N = 141) and in 2021 (during the pandemic; N = 151). Both surveys recorded the respondents’ perceived barriers to integrating new digital health technologies and the tools they currently used in their practice.

HCP use of telemedicine increased from 47% of respondents in 2019 to 81% in 2021, as did the use of mHealth sensors (2% vs 10%). Patient comfort with technology remained one of the biggest barriers to implementing new digital tools (40% vs 43%), while difficulty integrating digital tools into clinical practice became less common (40% vs 32%). Data management (19% vs 10%) and patient acceptability (19% vs 13%) were cited less often as barriers in 2021. Respondents’ thoughts on what can be most improved by digital technology shifted substantially, with increased access to care rising from 27% of responses in 2019 to 46% in 2021.

The pandemic has changed how HCPs perceive digital health technologies and how they implement these tools in clinical practice. A growing number of HCPs believe increased access to care is the outcome that technology can most improve.

Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, USA

With the rise of the cultural and creative industry, rural cultural and innovative products are gradually receiving market attention. Patients with mood disorders often require special psychological treatment due to emotional fluctuations and social difficulties. This study aims to explore the application of folk culture in the design of cultural and creative products and the therapeutic effect of combining rational emotional therapy on patients with mood disorders.

The study selected 50 rural cultural and creative products and analyzed their folk cultural elements in-depth. At the same time, 100 patients with mood disorders were selected and divided into experimental and control groups. A 6-month treatment period was conducted using cultural and creative products and a rational emotional therapy experimental group. The control group received routine treatment. The patient’s condition was evaluated using the Mood Disorder Questionnaire (MDQ).

The results show that in the design of cultural and creative products, folk culture can increase the product’s emotional value and market recognition. After six months of treatment, the experimental group patients’ emotional stability and social function significantly improved, and the total effective treatment rate reached 91%.

The folk cultural elements in rural cultural and creative products can add profound cultural value and improve market competitiveness. Combining rational emotional therapy can provide effective treatment methods for patients with mood disorders.